Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Fluorouracil + INCB161734 + Irinotecan + Leucovorin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent that interferes with DNA and RNA synthesis, thereby preventing cancer cell growth (PMID: 28520376). Adrucil (fluorouracil) is FDA-approved for use in patients with adenocarcinoma of the colon, rectum, breast, stomach, and pancreas (FDA.gov). |
| INCB161734 | INCB-161734|INCB 161734 | KRAS G12D Inhibitor 25 | INCB161734 selectively inhibits KRAS G12D, potentially resulting in decreased cell proliferation and tumor growth (Cancer Res (2024) 84 (6_Supplement): 5900). | |
| Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
| Leucovorin | Wellcovorin | Calcium folinate|Calcium citrovorum factor|folinic acid | Chemotherapy - Antimetabolite 14 | Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06179160 | Phase I | Cetuximab + INCB161734 INCB161734 + Retifanlimab Fluorouracil + INCB161734 + Irinotecan + Leucovorin + Oxaliplatin INCA33890 + INCB161734 INCB161734 Gemcitabine + INCB161734 + Nab-paclitaxel Fluorouracil + INCB161734 + Leucovorin + Oxaliplatin Fluorouracil + INCB161734 + Irinotecan + Leucovorin | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | AUS | 1 |